![Ian Keith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Ian Keith has a current job as a Director at MAP Patient Access Ltd.
Postes actifs de Ian Keith
Sociétés | Poste | Début |
---|---|---|
MAP Patient Access Ltd.
![]() MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Directeur/Membre du Conseil | 01/02/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
MAP Patient Access Ltd.
![]() MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Commercial Services |